Yogender Pal Khasa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yogender Pal Khasa has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Babbal
14 shared publicationsShilpa Mohanty
Department of Microbiology, University of Delhi South Campus, New Delhi, 110 021, India
13 shared publicationsAdivitiya
12 shared publicationsVikas Kumar Dagar
University of Delhi South Campus, New Delhi, India
6 shared publicationsMohini Talwar
Department of Microbiology, University of Delhi South Campus, New Delhi, India
3 shared publicationsNirmala Devi
Department of Microbiology, University of Delhi South Campus, New Delhi, 110 021, India
3 shared publications
Latest Publications
- 14 October 2026
- Published by Springer Nature in Bioprocess and Biosystems Engineering
- p. 1-23
Tailoring high-cell-density fed-batch fermentation strategies to produce Russell’s viper venom-specific single-domain antibody in E. coli
Attributes of camelid-derived single-domain antibodies (sdAbs), such as enhanced antigen specificity, improved solubility and stability, efficient tissue penetration, and superior biodistribution, make them preferable therapeutics for diverse applications, including the treatment of cancers, neurological disorders, infectious diseases, and intoxication. Limited availability and high cost of antivenoms necessitate the discovery of alternative neutralizers. This investigation presents a proof of concept for developing a cost-effective Escherichia coli-based platform to produce high yields of an sdAb specific to Russell’s viper venom, denoted as ‘FRV’. The gene encoding the FRV protein was cloned into the pET28a vector, and expression was evaluated in shake flasks using both complex and chemically defined media at various temperatures, achieving a maximum concentration of ~ 190 mg/L and a specific product yield (YP/X) of 38 mg/g DCW. Solubility assessments of FRV sdAb indicated the formation of inclusion bodies (IBs) under all tested conditions. Multiple strategies were employed to simplify and enhance IB solubilization, refolding, and Ni-NTA purification, yielding ~ 85% recovery and ~ 90% purity. Additionally, FRV immunoreactivity and neutralization activity were further validated by immunoblotting, ELISA, and in vitro phospholipase inhibition assay. FRV sdAb expression was subsequently scaled up via fed-batch fermentation in 1 L and 2.5 L cultures using different optimization strategies. Systematic evaluation of cultivation parameters, including induction OD600, post-induction temperature, feed composition, and antibiotic levels, yielded a maximum FRV concentration of ~ 3.8 g/L and a YP/X of 59 mg/g DCW. Among the fermentation strategies evaluated, induction temperature was identified as a key factor influencing product yields and plasmid stability. Graphical abstract
- 14 October 2026
- Published by Springer Nature in Bioprocess and Biosystems Engineering
- p. 1-23
Tailoring high-cell-density fed-batch fermentation strategies to produce Russell’s viper venom-specific single-domain antibody in E. coli
Attributes of camelid-derived single-domain antibodies (sdAbs), such as enhanced antigen specificity, improved solubility and stability, efficient tissue penetration, and superior biodistribution, make them preferable therapeutics for diverse applications, including the treatment of cancers, neurological disorders, infectious diseases, and intoxication. Limited availability and high cost of antivenoms necessitate the discovery of alternative neutralizers. This investigation presents a proof of concept for developing a cost-effective Escherichia coli-based platform to produce high yields of an sdAb specific to Russell’s viper venom, denoted as ‘FRV’. The gene encoding the FRV protein was cloned into the pET28a vector, and expression was evaluated in shake flasks using both complex and chemically defined media at various temperatures, achieving a maximum concentration of ~ 190 mg/L and a specific product yield (YP/X) of 38 mg/g DCW. Solubility assessments of FRV sdAb indicated the formation of inclusion bodies (IBs) under all tested conditions. Multiple strategies were employed to simplify and enhance IB solubilization, refolding, and Ni-NTA purification, yielding ~ 85% recovery and ~ 90% purity. Additionally, FRV immunoreactivity and neutralization activity were further validated by immunoblotting, ELISA, and in vitro phospholipase inhibition assay. FRV sdAb expression was subsequently scaled up via fed-batch fermentation in 1 L and 2.5 L cultures using different optimization strategies. Systematic evaluation of cultivation parameters, including induction OD600, post-induction temperature, feed composition, and antibiotic levels, yielded a maximum FRV concentration of ~ 3.8 g/L and a YP/X of 59 mg/g DCW. Among the fermentation strategies evaluated, induction temperature was identified as a key factor influencing product yields and plasmid stability. Graphical abstract
- 2 May 2026
- Published by Springer Nature in Bioprocess and Biosystems Engineering
Designing strategies for high-level production of peptide-N-glycosidase F (PNGase F) from Flavobacterium meningosepticum using high cell density fed-batch culture of E. coli
Protein N-glycosylation is a crucial post-translational modification that regulates cellular processes such as cell signalling, development, and autophagy. Abnormalities in protein glycosylation can manifest in life-threatening conditions, such as cancer. N-glycan analysis is crucial for determining the underlying cause of disease. The characterization of N-linked glycans is achieved through the removal of the carbohydrate moiety using deglycosylating enzymes. Peptide-N-glycosidase F (PNGase F) is a glycoamidase that hydrolyzes the amide bond in glycosamide by specifically cleaving at the innermost N-acetylglucosamine (GlcNAc). Although PNGase F has significant therapeutic applications, its widespread commercial use is limited by its high cost. This study focused on heterologous expression of Flavobacterium meningosepticum PNGase F in E. coli BL21 (DE3) and SHuffle® cells, in which the protein was partially soluble. The E. coli SHuffle® cells yielded 210.41 mg/L of PNGase F in TB glycerol medium in shake flasks, with a corresponding YP/X of 47.20 mg/g DCW. Expression studies in E. coli BL21 (DE3) cells yielded inclusion bodies (IBs) that were solubilized, yielding activity comparable to that of the soluble form. Furthermore, the fed-batch cultivation in E. coli BL21 (DE3) cells produced 5.87 g/L of IBs with a final OD600 of 176. Therefore, this study investigates the potential of alternative E. coli hosts as cost-effective production platforms for PNGase F.
- 2 May 2026
- Published by Springer Nature in Bioprocess and Biosystems Engineering
Designing strategies for high-level production of peptide-N-glycosidase F (PNGase F) from Flavobacterium meningosepticum using high cell density fed-batch culture of E. coli
Protein N-glycosylation is a crucial post-translational modification that regulates cellular processes such as cell signalling, development, and autophagy. Abnormalities in protein glycosylation can manifest in life-threatening conditions, such as cancer. N-glycan analysis is crucial for determining the underlying cause of disease. The characterization of N-linked glycans is achieved through the removal of the carbohydrate moiety using deglycosylating enzymes. Peptide-N-glycosidase F (PNGase F) is a glycoamidase that hydrolyzes the amide bond in glycosamide by specifically cleaving at the innermost N-acetylglucosamine (GlcNAc). Although PNGase F has significant therapeutic applications, its widespread commercial use is limited by its high cost. This study focused on heterologous expression of Flavobacterium meningosepticum PNGase F in E. coli BL21 (DE3) and SHuffle® cells, in which the protein was partially soluble. The E. coli SHuffle® cells yielded 210.41 mg/L of PNGase F in TB glycerol medium in shake flasks, with a corresponding YP/X of 47.20 mg/g DCW. Expression studies in E. coli BL21 (DE3) cells yielded inclusion bodies (IBs) that were solubilized, yielding activity comparable to that of the soluble form. Furthermore, the fed-batch cultivation in E. coli BL21 (DE3) cells produced 5.87 g/L of IBs with a final OD600 of 176. Therefore, this study investigates the potential of alternative E. coli hosts as cost-effective production platforms for PNGase F.
- 25 April 2025
- Published by Springer Nature
- p. 549-589
Emerging Metabolic Engineering and Synthetic Biology Strategies in the Development of Lignocellulosic Biomass-Based Biorefineries
- 25 April 2025
- Published by Springer Nature
- p. 549-589
Emerging Metabolic Engineering and Synthetic Biology Strategies in the Development of Lignocellulosic Biomass-Based Biorefineries
- Open Access
Challenges and Opportunities in the Process Development of Chimeric Vaccines
Vaccines are integral to human life to protect them from life-threatening diseases. However, conventional vaccines often suffer limitations like inefficiency, safety concerns, unavailability for non-culturable microbes, and genetic variability among pathogens. Chimeric vaccines combine multiple antigen-encoding genes of similar or different microbial strains to protect against hyper-evolving drug-resistant pathogens. The outbreaks of dreadful diseases have led researchers to develop economical chimeric vaccines that can cater to a large population in a shorter time. The process development begins with computationally aided omics-based approaches to design chimeric vaccines. Furthermore, developing these vaccines requires optimizing upstream and downstream processes for mass production at an industrial scale. Owing to the complex structures and complicated bioprocessing of evolving pathogens, various high-throughput process technologies have come up with added advantages. Recent advancements in high-throughput tools, process analytical technology (PAT), quality-by-design (QbD), design of experiments (DoE), modeling and simulations, single-use technology, and integrated continuous bioprocessing have made scalable production more convenient and economical. The paradigm shift to innovative strategies requires significant attention to deal with major health threats at the global scale. This review outlines the challenges and emerging avenues in the bioprocess development of chimeric vaccines.
Open AccessChallenges and Opportunities in the Process Development of Chimeric Vaccines
Vaccines are integral to human life to protect them from life-threatening diseases. However, conventional vaccines often suffer limitations like inefficiency, safety concerns, unavailability for non-culturable microbes, and genetic variability among pathogens. Chimeric vaccines combine multiple antigen-encoding genes of similar or different microbial strains to protect against hyper-evolving drug-resistant pathogens. The outbreaks of dreadful diseases have led researchers to develop economical chimeric vaccines that can cater to a large population in a shorter time. The process development begins with computationally aided omics-based approaches to design chimeric vaccines. Furthermore, developing these vaccines requires optimizing upstream and downstream processes for mass production at an industrial scale. Owing to the complex structures and complicated bioprocessing of evolving pathogens, various high-throughput process technologies have come up with added advantages. Recent advancements in high-throughput tools, process analytical technology (PAT), quality-by-design (QbD), design of experiments (DoE), modeling and simulations, single-use technology, and integrated continuous bioprocessing have made scalable production more convenient and economical. The paradigm shift to innovative strategies requires significant attention to deal with major health threats at the global scale. This review outlines the challenges and emerging avenues in the bioprocess development of chimeric vaccines.
- 19 November 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 255, 128258
Designing Ubiquitin-like protease 1 (Ulp1) based nano biocatalysts: A promising technology for SUMO fusion proteins
- 19 November 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 255, 128258
Designing Ubiquitin-like protease 1 (Ulp1) based nano biocatalysts: A promising technology for SUMO fusion proteins
- 14 May 2023
- Published by Springer Nature
- p. 513-569
Heterologous Gene Expression in Pichia pastoris: Success Stories and Commercial Ventures
- 14 May 2023
- Published by Springer Nature
- p. 513-569
Heterologous Gene Expression in Pichia pastoris: Success Stories and Commercial Ventures
- 12 August 2022
- Published by Springer Nature in 3 Biotech
- Vol. 12 (9) , 1-11
Effect of N-glycosylation on secretion, stability, and biological activity of recombinant human interleukin-3 (hIL-3) in Pichia pastoris
Human interleukin-3 (hIL-3) is a clinically important cytokine used to treat hematological malignancies, bone marrow transplantation, cytopenias, and immunological disorders. The cloning of hIL-3 gene was previously reported by our group, where its expression was optimized under methanol-inducible AOX1 promoter having N-terminal α mating factor signal sequence from Saccharomyces cerevisiae. This study investigated the role of glycosylation pattern on its molecular stability, secretion efficiency, and biological activity using the mutagenesis approach. The two N-linked glycosylation positions at N15th (Asn15) and N70th (Asn70) were sequentially mutated to generate three recombinant hIL-3 variants, i.e., N15A, N70A, and N15/70A. Asparagine at these positions was replaced with non-polar alanine amino acid (Ala, A). The alteration of N-linked glycosylation sites was disadvantageous to its efficient secretion in Pichia pastoris, where a 52.32%, 36.48%, 71.41% lower production was observed in N15A, N70A, and N15/70A mutants, respectively, as compared to native control. The fully glycosylated native hIL-3 protein showed higher thermal stability over its deglycosylated counterparts. The biological activity of native, N15A, N70A, and N15/70A hIL-3 protein was evaluated, where N15/70A mutant showed slightly higher proliferation efficacy than other combinations.
- 12 August 2022
- Published by Springer Nature in 3 Biotech
- Vol. 12 (9) , 1-11
Effect of N-glycosylation on secretion, stability, and biological activity of recombinant human interleukin-3 (hIL-3) in Pichia pastoris
Human interleukin-3 (hIL-3) is a clinically important cytokine used to treat hematological malignancies, bone marrow transplantation, cytopenias, and immunological disorders. The cloning of hIL-3 gene was previously reported by our group, where its expression was optimized under methanol-inducible AOX1 promoter having N-terminal α mating factor signal sequence from Saccharomyces cerevisiae. This study investigated the role of glycosylation pattern on its molecular stability, secretion efficiency, and biological activity using the mutagenesis approach. The two N-linked glycosylation positions at N15th (Asn15) and N70th (Asn70) were sequentially mutated to generate three recombinant hIL-3 variants, i.e., N15A, N70A, and N15/70A. Asparagine at these positions was replaced with non-polar alanine amino acid (Ala, A). The alteration of N-linked glycosylation sites was disadvantageous to its efficient secretion in Pichia pastoris, where a 52.32%, 36.48%, 71.41% lower production was observed in N15A, N70A, and N15/70A mutants, respectively, as compared to native control. The fully glycosylated native hIL-3 protein showed higher thermal stability over its deglycosylated counterparts. The biological activity of native, N15A, N70A, and N15/70A hIL-3 protein was evaluated, where N15/70A mutant showed slightly higher proliferation efficacy than other combinations.
- 18 April 2022
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 209 (Pt A) , 1001-1019
Heterologous expression of novel SUMO proteases from Schizosaccharomyces pombe in E. coli: Catalytic domain identification and optimization of product yields
- 18 April 2022
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 209 (Pt A) , 1001-1019
Heterologous expression of novel SUMO proteases from Schizosaccharomyces pombe in E. coli: Catalytic domain identification and optimization of product yields